V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008696 | 330005495 | 1.64 | 71.5 | Palliative (P) | 2019-01-22 | 2019-01-23 | CNS LGG 2004 03 vinc weekly+ carbo | 2 | null | 330020831 | EMA/CO |
| 330008697 | 330005496 | 1.68 | null | Curative (C) | 2014-05-17 | 2014-05-19 | CYTARABINE + DAUNORUBICIN + ETOPOSIDE | N | N | 330020832 | CAPECITABINE + CETUXIMAB + CISPLATIN |
| 330008698 | 330005498 | 1.67 | 92.2 | Palliative (P) | 2014-08-31 | 2014-09-01 | BORTEZOMIB + RITUXIMAB | N | N | 330020835 | IVA |
| 330008699 | 330005498 | null | 70.6 | Palliative (P) | 2015-03-10 | 2015-03-23 | Cyclophosphamide High Dose | N | N | 330020835 | EDP |
| 330008700 | 330005498 | 1.62 | 88 | Curative (C) | 2012-04-10 | 2014-12-15 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | N | null | 330020835 | DHAP |
| 330008701 | 330012860 | 1.67 | 7.5 | null | 2017-10-11 | 2017-12-13 | UKALL14- Intens/CNS Proph | 1 | N | 330020871 | CLADRIBINE |
| 330008703 | 330008999 | 0 | 88.8 | Curative (C) | 2013-12-24 | 2013-12-24 | UKALL14- Cons Cycle 1 | N | N | 330020894 | AML18 TRIAL |
| 330008704 | 330009000 | null | 53.3 | Disease modification (D) | null | 2017-07-03 | Cyclophosphamide + Vincristine | null | null | 330020898 | MAP + MIFAMURTIDE |
| 330008705 | 330005502 | 1.71 | null | Curative (C) | 2017-03-12 | 2017-03-12 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 2 | null | 330020902 | AML18 TRIAL |
| 330008706 | 330005504 | 1.8 | 68.5 | Curative (C) | 2014-09-26 | 2014-10-17 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330020923 | CLADRIBINE |
| 330008707 | 330005506 | 1.55 | 95.2 | Palliative (P) | 2014-11-06 | 2014-11-06 | CNS LGG Irinotecan & Bevacizumab | 2 | N | 330020925 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 330008708 | 330005507 | 1.71 | null | Neo-adjuvant (N) | 2017-09-29 | 2017-10-28 | Hydroxycarbamide | N | N | 330020929 | ADE |
| 330008709 | 330005508 | 1.64 | 13.2 | Palliative (P) | 2017-10-27 | 2017-10-27 | ALL UKALL2003 TRIAL | N | null | 330020955 | EMA |
| 330008710 | 330005509 | 1.62 | 76 | Palliative (P) | 2014-07-11 | 2014-08-05 | Cyclophosphamide High Dose | N | N | 330020955 | NILOTINIB |
| 330008711 | 330005509 | 1.69 | null | Curative (C) | 2015-01-27 | 2015-02-08 | CAPECITABINE + CARBOPLATIN + Cetuximab | 2 | N | 330020955 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008712 | 330005509 | 1.64 | 65.4 | Palliative (P) | 2015-09-13 | 2015-10-15 | Ipilimumab | N | N | 330020955 | IDARUBICIN |
| 330008713 | 330005513 | 1.63 | 45.1 | Palliative (P) | 2014-11-17 | 2014-11-22 | DACTINOMYCIN | N | null | 330020980 | BORTEZOMIB |
| 330008714 | 330009005 | 1.64 | 66 | Palliative (P) | 2018-03-10 | 2018-04-03 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | N | N | 330020984 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330008715 | 330005514 | 1.8 | 43.1 | Palliative (P) | 2013-11-15 | 2014-02-13 | Bendamustine +/- Prednisolone | N | N | 330020988 | BEP |
| 330008716 | 330010883 | 1.59 | 53.1 | null | 2014-04-23 | 2014-04-27 | FMD Oral | N | null | 330020998 | UKALL2014 |
| 330008717 | 330005516 | null | null | Palliative (P) | 2014-09-30 | 2014-11-23 | BEP 5 Day | Y | N | 330020998 | BEP |
| 330008718 | 330010885 | null | 20.6 | Curative (C) | 2015-01-07 | 2015-01-08 | CYTARABINE | N | N | 330021023 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330008719 | 330010885 | 0 | 71.45 | Palliative (P) | null | 2013-07-27 | MVAC Accelerated | N | N | 330021023 | RMS 2005 TRIAL |
| 330008720 | 330005519 | null | null | Disease modification (D) | 2015-07-28 | 2015-07-29 | ATG + Busulfan + Fludarabine | N | N | 330021026 | AML17 TRIAL |
| 330008721 | 330005520 | 1.78 | 0 | Neo-adjuvant (N) | 2016-03-16 | 2016-06-02 | IVA | N | N | 330021030 | CETUXIMAB + CISPLATIN + FU |
| 330008723 | 330005522 | 1.77 | null | null | 2017-02-12 | 2017-03-07 | CISPLATIN + ETOPOSIDE + PACLITAXEL | N | N | 330021050 | BUSULFAN + MELPHALAN |
| 330008724 | 330005523 | 1.65 | 11.3 | Palliative (P) | null | 2014-07-16 | Midostaurin | null | N | 330021050 | CISPLATIN + FLUOROURACIL + RT |
| 330008725 | 330009013 | 0 | null | Adjuvant (A) | 2019-01-25 | 2019-02-02 | CYTARABINE + MITOXANTRONE | 2 | null | 330021058 | TRIPLE INTRATHECAL |
| 330008726 | 330009013 | 1.65 | 70 | Neo-adjuvant (N) | 2014-11-08 | 2014-12-06 | Doxorubicin + Methotrexate | N | N | 330021058 | CLADRIBINE |
| 330008727 | 330009013 | 1.7 | 40 | null | 2013-09-23 | 2013-10-04 | CAPECITABINE + CARBOPLATIN + Cetuximab | 01 | N | 330021058 | CARBOPLATIN + CETUXIMAB + FU |
| 330008728 | 330005525 | 0 | null | Palliative (P) | 2016-12-03 | 2017-06-23 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 330021074 | VINCRISTINE |
| 330008730 | 330010889 | 1.65 | 44.3 | Adjuvant (A) | 2014-07-17 | 2014-07-28 | Carboplatin + Docetaxel | 2 | N | 330021084 | MAP + MIFAMURTIDE |
| 330008731 | 330010889 | 1.6 | 16 | Palliative (P) | 2015-02-19 | 2015-03-03 | MERCAPTOPURINE + METHOTREXATE | N | N | 330021084 | EDP |
| 330008732 | 330005526 | 1.11 | 90.85 | Palliative (P) | null | 2014-07-04 | CYCLOPHOSPHAMIDE + FLUDARABINE | null | null | 330021093 | AML19 TRIAL |
| 330008733 | 330012523 | 1.77 | 61.6 | Disease modification (D) | 2013-11-17 | 2013-12-27 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330021094 | PEMBROLIZUMAB |
| 330008734 | 330012523 | 1.68 | 15.76 | Curative (C) | 2014-11-02 | 2014-11-17 | AFATINIB | N | N | 330021094 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330008736 | 330005536 | null | 88.8 | Neo-adjuvant (N) | 2017-12-27 | 2017-12-27 | FLUOROURACIL + MITOMYCIN | Y | null | 330021104 | VINORELBINE |
| 330008737 | 330005536 | 1.75 | 74.5 | Palliative (P) | 2017-08-24 | 2017-09-19 | Fludarabine + Melphalan RIC Allo | N | N | 330021104 | BLEOMYCIN + VINCRISTINE |
| 330008738 | 330005537 | 1.6 | 71.7 | Neo-adjuvant (N) | 2014-11-05 | 2015-01-15 | EMA/CO | N | null | 330021119 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008739 | 330005537 | null | 50.7 | Palliative (P) | 2016-10-10 | 2016-10-29 | Carboplatin + Doxorubicin | N | null | 330021119 | EMA |
| 330008740 | 330010894 | 1.67 | 66 | Curative (C) | null | 2015-08-25 | Dox + HD Mtx (post PAM) | null | N | 330021120 | CARBOPLATIN + VINCRISTINE |
| 330008741 | 330005540 | 1.84 | 12.3 | Curative (C) | 2015-03-28 | 2015-04-18 | LIPOSOMAL DAUNORUBICIN | N | N | 330021122 | IMATINIB |
| 330008742 | 330009022 | 1.63 | null | Curative (C) | 2018-11-28 | 2018-12-10 | Ifosfamide | 02 | N | 330021126 | EDP + MITOTANE |
| 330008743 | 330009022 | null | null | null | 2016-03-26 | 2016-07-16 | Cyclophosphamide + Etoposide (PO) | 02 | N | 330021126 | PEMBROLIZUMAB |
| 330008744 | 330005541 | 1.67 | 80.6 | Palliative (P) | 2013-12-07 | 2013-12-17 | Pemetrexed | 02 | N | 330021150 | UKALL2014 |
| 330008745 | 330009023 | null | null | Curative (C) | null | 2014-11-20 | CNS LGG 2004 03 vinc weekly+ carbo | N | Y | 330021151 | BENDAMUSTINE |
| 330008746 | 330005542 | 1.73 | 18.45 | Curative (C) | 2016-08-04 | 2017-01-19 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 330021153 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 330008748 | 330005544 | 0.9 | 124.5 | Neo-adjuvant (N) | 2014-11-13 | 2014-12-10 | Doxorubicin + Methotrexate | N | N | 330021182 | CVD (NEUROENDOCRINE) |
| 330008749 | 330005544 | 1.82 | 101.2 | Adjuvant (A) | 2015-08-31 | 2015-10-11 | Alemtuzumab | N | N | 330021182 | IFOSFAMIDE |
| 330008750 | 330010897 | 1.75 | 67.6 | Curative (C) | 2016-12-14 | 2016-12-29 | Dox + HD Mtx (post PAM) | N | N | 330021203 | CYCLOPHOSPHAMIDE HIGH DOSE |